Vericel to Present at the Morgan Stanley Global Healthcare Conference
06 Setembro 2023 - 9:30AM
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies
for the sports medicine and severe burn care markets, today
announced that Nick Colangelo, President and CEO will participate
in a fireside chat at the Morgan Stanley 21st Annual Global
Healthcare Conference at 7:30 a.m. ET on Tuesday, September 12,
2023.
A webcast of the presentation will be available on the Investor
Relations section of the Vericel Corporation website at:
http://investors.vcel.com.
About Vericel Corporation
Vericel is a leader in advanced therapies for sports medicine
and severe burn care. The Company manufactures and markets two cell
therapy products and one specialty biologic product in the United
States. MACI® (autologous cultured chondrocytes on porcine
collagen membrane) is an autologous cellularized scaffold product
indicated for the repair of symptomatic, single or multiple
full-thickness cartilage defects of the knee with or without bone
involvement in adults. Epicel® (cultured epidermal autografts)
is a permanent skin replacement for the treatment of patients with
deep dermal or full thickness burns greater than or equal to 30% of
total body surface area. Vericel also holds an exclusive license
for North American rights to NexoBrid® (anacaulase-bcdb), a
biological orphan product containing proteolytic enzymes, which is
indicated for the removal of eschar in adults with deep
partial-thickness and/or full-thickness burns. For more
information, please visit www.vcel.com.
Epicel® and MACI® are registered trademarks of Vericel
Corporation. NexoBrid® is a registered trademark of MediWound
Ltd. and is used under license to Vericel Corporation. © 2023
Vericel Corporation. All rights reserved.
Investor Contacts:Eric Burnsir@vcel.com+1 (734)
418-4411
Media Contact:Julie Downsmedia@vcel.com
Vericel (NASDAQ:VCEL)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Vericel (NASDAQ:VCEL)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024